GlassScriptPhysician profile
Brandon Jamal Anderson
NPI 1013335082
$6,951.26
in general payments reported to CMS, 2019-2025
43 companies · $1,704 in 2025
The $1,704 reported for 2025 was more than what 80% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $382 · 2023: $1,480 · 2024: $3,386 · 2025: $1,704.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,570.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,569.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endomagnetics LTD | $1,363.16 | 2023-2024 | Magtrace, Magseed |
| Astrazeneca Pharmaceuticals LP | $1,053.71 | 2022-2025 | Lynparza, Enhertu, Datroway |
| Daiichi Sankyo INC. | $517.25 | 2022-2025 | Enhertu, Vanflyta, Injectafer |
| Novartis Pharmaceuticals Corporation | $501.90 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $486.87 | 2022-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Davol INC. | $289.52 | 2023-2025 | Phasix Mesh, Arista |
| Janssen Biotech, INC. | $214.42 | 2023-2025 | Tecvayli, Erleada, Talvey |
| Incyte Corporation | $205.10 | 2022-2025 | Monjuvi, Jakafi, Pemazyre |
| Eisai INC. | $178.55 | 2023-2025 | |
| Pfizer INC. | $172.39 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $154.07 | 2022-2024 | Iclusig, Ninlaro, Fruzaqla |
| Tactile Systems Technology INC | $144.04 | 2025 | Flexitouch Plus, Nimbl |
| Merit Medical Systems INC | $124.04 | 2024 | Savi Scout |
| Rigel Pharmaceuticals, INC. | $123.61 | 2023-2025 | Rezlidhia, Tavalisse, Gavreto |
| Hologic INC | $111.61 | 2024 | Localizer |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tersera Therapeutics LLC | $96.19 | 2023-2025 | Zoladex |
| Baxter Healthcare | $94.11 | 2024 | Perclot |
| Lilly USA, LLC | $75.88 | 2025 | Verzenio, Jaypirca |
| Genentech USA, INC. | $73.37 | 2023-2025 | Itovebi, Tecentriq Hybreza, Phesgo |
| Emd Serono, INC. | $71.65 | 2023-2025 | Tepmetko |
| Amgen INC. | $70.97 | 2022-2023 | Nplate, Vectibix, Xgeva |
| Stryker Corporation | $65.92 | 2023 | Spy-Phi System |
| Bayer Healthcare Pharmaceuticals INC. | $63.58 | 2022-2025 | |
| Iovance Biotherapeutics, INC. | $58.55 | 2025 | Amtagvi |
| Genmab U.S., INC. | $55.99 | 2024 | Epkinly |
| Sun Pharmaceutical Industries INC. | $54.06 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $54.06 | 2024-2025 | Libtayo |
| Karyopharm Therapeutics INC. | $49.62 | 2024-2025 | Xpovio |
| Pharmacosmos Therapeutics INC. | $46.23 | 2025 | Monoferric |
| Genzyme Corporation | $45.30 | 2025 | |
| Tempus Ai, INC | $40.83 | 2024 | |
| Becton, Dickinson and Company | $37.83 | 2022 | |
| Coherus Oncology, INC. | $35.90 | 2024 | |
| Seagen INC. | $35.13 | 2023 | Adcetris, Padcev |
| Syndax Pharmaceuticals, INC. | $28.42 | 2025 | |
| Alexion Pharmaceuticals, INC. | $28.34 | 2023 | Ultomiris |
| Legend Biotech USA INC. | $25.99 | 2025 | Carvykti |
| Aveo Pharmaceuticals, INC. | $24.70 | 2025 | |
| Morphosys, US INC. | $23.09 | 2023 | Monjuvi |
| Caris Mpi, INC. | $14.64 | 2025 | Mi Cancer Seek |
| Tolmar, INC. | $14.03 | 2025 | Eligard, Rubraca |
| Pharmaand Gmbh | $14.03 | 2025 | Rubraca |
| Blueprint Medicines Corporation | $12.61 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.